Inhaled Tacrolimus, Add-on to Inhaled Corticosteroids & Long Acting B2 Agonists in Moderate to Severe Persistent Asthma

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00189722

Enrollment

160

Registered

2005-09-19

Start date

Unknown

Completion date

2005-07-31

Last updated

2008-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma, Bronchial, Bronchial Asthma

Keywords

Tacrolimus, Immunosuppressant, Anti-asthmatic drug, Administration, inhalation

Brief summary

This study will evaluate the efficacy and safety of tacrolimus in patients with asthma.

Interventions

DRUGTacrolimus

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Diagnosis of asthma * Patients treated with inhaled corticosteroid and long acting beta 2 agonist * FEV1(forced expiratory volume in 1 second)\>50% to 80%

Exclusion criteria

* Respiratory infection within 2weeks * Asthma exacerbation within 6 weeks

Countries

Czechia, Germany, Poland, Russia, Ukraine

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026